The latest update is out from JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ).
JCR Pharmaceuticals has commenced construction of a new drug product plant at the Kobe Science Park Center, aimed at enhancing its vaccine production capabilities in pandemic emergencies. The project, supported by government subsidies, will integrate with an existing API plant to strengthen JCR’s manufacturing capacity, although it is expected to have a minor impact on the company’s financial results for the current fiscal year.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a biopharmaceutical company engaged in research, development, and manufacturing. The company focuses on developing protein therapy products for lysosomal storage disorders using its proprietary blood-brain-barrier penetration technology, J-Brain Cargo®.
YTD Price Performance: -13.67%
Average Trading Volume: 467,011
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: Yen64.85B
Find detailed analytics on 4552 stock on TipRanks’ Stock Analysis page.